Cell Biology
NOX5 in Human Spermatozoa: EXPRESSION, FUNCTION, AND REGULATION*

https://doi.org/10.1074/jbc.M111.314955Get rights and content
Under a Creative Commons license
open access

Physiological and pathological processes in spermatozoa involve the production of reactive oxygen species (ROS), but the identity of the ROS-producing enzyme system(s) remains a matter of speculation. We provide the first evidence that NOX5 NADPH oxidase is expressed and functions in human spermatozoa. Immunofluorescence microscopy detected NOX5 protein in both the flagella/neck region and the acrosome. Functionally, spermatozoa exposed to calcium ionophore, phorbol ester, or H2O2 exhibited superoxide anion production, which was blocked by addition of superoxide dismutase, a Ca2+ chelator, or inhibitors of either flavoprotein oxidases (diphenylene iododonium) or NOX enzymes (GKT136901). Consistent with our previous overexpression studies, we found that H2O2-induced superoxide production by primary sperm cells was mediated by the non-receptor tyrosine kinase c-Abl. Moreover, the HV1 proton channel, which was recently implicated in spermatozoa motility, was required for optimal superoxide production by spermatozoa. Immunoprecipitation experiments suggested an interaction among NOX5, c-Abl, and HV1. H2O2 treatment increased the proportion of motile sperm in a NOX5-dependent manner. Statistical analyses showed a pH-dependent correlation between superoxide production and enhanced sperm motility. Collectively, our findings show that NOX5 is a major source of ROS in human spermatozoa and indicate a role for NOX5-dependent ROS generation in human spermatozoa motility.

Calcium
NADPH Oxidase
Reactive Oxygen Species (ROS)
Signal Transduction
Spermatozoa
Tyrosine Protein Kinase (Tyrosine Kinase)
Motility
Proton Channel

Cited by (0)

*

This work was supported, in whole or in part, by National Institutes of Health Grants T32 HL04776 (to A. E. J.), UL1 RR025767 (to A. E. J.), Clinical and Translational Science Awards pilot funding (to A. E. J.), KL2 RR025766 (to A. E. J.), K01 DK084297 (to A. E. J.), and Career Development Award R01-GM087507 (to T. E. D.) and an award from the Iacocca Family Foundation (to B. M.). Robert Clark is a scientific co-founder, member of the Scientific Advisory Board, and equity holder in GenKyoTex SA, a Swiss biotechnology start-up company with a primary goal of developing clinically useful inhibitors of the NOX family of NADPH oxidases.

3

GenKyoTex, personal communication.